Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pediatric Nephrology
Published in: Pediatric Nephrology 11/2013

01-11-2013 | Original Article

FGF23 and mineral metabolism in the early post-renal transplantation period

Authors: Katherine Wesseling-Perry, Renata C. Pereira, Eileen Tsai, Robert Ettenger, Harald Jüppner, Isidro B. Salusky

Published in: Pediatric Nephrology | Issue 11/2013

Login to get access

Abstract

Background

The relationship between fibroblast growth factor 23 (FGF23) and vitamin D production and catabolism post-renal transplantation has not been characterized.

Methods

Circulating creatinine, calcium, phosphorus, albumin, parathyroid hormone, FGF23, and 1,25(OH)2 vitamin D (calcitriol) values were obtained pre-transplantation, daily post-operatively for 5 days, and at 6 months post-transplantation in 44 patients aged 16.4 ± 0.4 years undergoing renal transplantation at UCLA from 1 August 2005 through to 30 April 2007. 25(OH) Vitamin D and 24,25(OH)2 vitamin D concentrations were obtained at baseline and on post-operative days 5 and 180, and urinary concentrations of creatinine, phosphorus, and FGF23 were measured on post-operative days 1, 3, 5, and 180.

Results

Circulating phosphate concentrations declined more rapidly and the fractional excretion of phosphorus was higher in the first week post-transplantation in subjects with higher FGF23 values. Fractional excretion of FGF23 was low at all time-points. Circulating 1,25(OH)2 vitamin D levels rose more rapidly and were consistently higher in patients with lower FGF23 values; however, 25(OH) vitamin D and 24,25(OH)2 vitamin D values were unrelated to FGF23 concentrations.

Conclusions

Inhibition of renal 1α-hydroxylase, rather than stimulation of 24-hydroxylase, may primarily contribute to the relationship between FGF23 values and calcitriol. The rapid decline in FGF23 levels post-transplantation in our patient cohort was not mediated solely by the filtration of intact FGF23 by the new kidney.
Literature
1.
Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16:2205–2215PubMedCrossRef
2.
Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, Juppner H, Salusky IB (2009) Relationship between plasma FGF-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 94:511–517PubMedCrossRef
3.
Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P (2007) Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18:2600–2608PubMedCrossRef
4.
Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M (2011) Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305:2432–2439PubMedCrossRef
5.
Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119:2545–2552PubMedCrossRef
6.
Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C (2009) Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 24:948–955PubMedCrossRef
7.
Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584–592PubMedCrossRef
8.
Wesseling-Perry K, Tsai EW, Ettenger RB, Juppner H, Salusky IB (2011) Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23? Nephrol Dial Transplant 26:3779–3784PubMedCrossRef
9.
Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, Kiss I, Rosivall L, Kosa J, Lakatos P, Kovesdy CP, Mucsi I (2011) Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 22:956–966PubMedCrossRef
10.
Garabedian M, Silve C, Levy-Bentolila D, Bourdeau A, Ulmann A, Nguyen TM, Lieberherr M, Broyer M, Balsan S (1981) Changes in plasma 1,25 and 24,25-dihydroxyvitamin D after renal transplantation in children. Kidney Int 20:403–410PubMedCrossRef
11.
Reinhardt W, Bartelworth H, Jockenhovel F, Schmidt-Gayk H, Witzke O, Wagner K, Heemann UW, Reinwein D, Philipp T, Mann K (1998) Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant 13:436–442PubMedCrossRef
12.
Nordal KP, Dahl E, Halse J, Aksnes L, Thomassen Y, Flatmark A (1992) Aluminum metabolism and bone histology after kidney transplantation: a one-year follow-up study. J Clin Endocrinol Metab 74:1140–1145PubMedCrossRef
13.
Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB (2003) Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64:2272–2279PubMedCrossRef
14.
Bhan I, Shah A, Holmes J, Isakova T, Gutierrez O, Burnett SA, Jüppner H, Wolf M (2006) Post-transplant hypophosphatemia: tertiary ‘Hyper-Phosphatoninism’? Kidney Int 70:1486–1494PubMedCrossRef
15.
Evenepoel P, Naesens M, Claes K, Kuypers D, Vanrenterghem Y (2007) Tertiary ‘hyperphosphatoninism’ accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 7:1193–1200PubMedCrossRef
16.
Pande S, Ritter CS, Rothstein M, Wiesen K, Vassiliadis J, Kumar R, Schiavi SC, Slatapolsky E, Brown AJ (2006) FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol 104:23–32CrossRef
17.
Isakova T, Xie H, Barchi-Chung A, Vargas G, Sowden N, Houston J, Wahl P, Lundquist A, Epstein M, Smith K, Contreras G, Ortega L, Lenz O, Briones P, Egbert P, Ikizler TA, Jueppner H, Wolf M (2011) Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol 6:2688–2695PubMedCrossRef
18.
Bhattacharyya N, Wiench M, Dumitrescu C, Connolly BM, Bugge TH, Patel HV, Gafni RI, Cherman N, Cho M, Hager GL, Collins MT (2012) Mechanism of FGF23 processing in fibrous dysplasia. J Bone Miner Res 27:1132–1141PubMedCrossRef
19.
Sato T, Fukagawa M, Uchida K, Katayama A, Nagasaka T, Matsuoka S, Goto N, Tominaga Y, Kobayashi T, Nakao A (2009) 1,25-dihydroxyvitamin D synthesis after renal transplantation: the role of fibroblast growth factor 23 and cyclosporine. Clin Transplant 23:368–374PubMedCrossRef
20.
Sanchez Fructuoso AI, Maestro ML, Calvo N, De La Orden V, Perez Flores I, Vidaurreta M, Valero R, Fernandez-Perez C, Barrientos A (2012) Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation. Transplant Proc 44:2551–2554PubMedCrossRef
21.
Kawarazaki H, Shibagaki Y, Fukumoto S, Kido R, Nakajima I, Fuchinoue S, Fujita T, Fukagawa M, Teraoka S (2011) The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study. Nephrol Dial Transplant 26:2691–2695PubMedCrossRef
22.
Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M (2005) Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 67:1171–1178PubMedCrossRef
23.
Gazdar AF, Dammin GJ (1970) Neural degeneration and regeneration in human renal transplants. N Engl J Med 283:222–224PubMedCrossRef
24.
Dai B, David V, Alshayeb HM, Showkat A, Gyamlani G, Horst RL, Wall BM, Quarles LD (2012) Assessment of 24,25(OH)2D levels does not support FGF23-mediated catabolism of vitamin D metabolites. Kidney Int 82:1061–1070PubMedCrossRef
25.
Spalding EM, Chamney PW, Farrington K (2002) Phosphate kinetics during hemodialysis: evidence for biphasic regulation. Kidney Int 61:655–667PubMedCrossRef
26.
Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling-Perry K, Wolf M, Salusky IB, Jüppner H (2010) Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 95:578–585PubMedCrossRef
27.
Bacchetta J, Dubourg L, Harambat J, Ranchin B, Bou-Jaoude P, Arnaud S, Carlier MC, Richard M, Cochat P (2010) The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab 95:1741–1748PubMedCrossRef
28.
Mendoza JM, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, Bazzano LA, Xie D, Kretzler M, Nessel L, Hamm LL, Negrea L, Leonard MB, Raj D, Wolf M (2012) Fibroblast Growth Factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol 7:1155–1162CrossRef
29.
Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson KB, Westin G, Larsson TE (2007) Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195:125–131PubMedCrossRef
30.
Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro O, Mohammadi M, Sirkis R, Naveh-Many T, Silver J (2007) The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003–4008PubMed
Metadata
Title
FGF23 and mineral metabolism in the early post-renal transplantation period
Authors
Katherine Wesseling-Perry
Renata C. Pereira
Eileen Tsai
Robert Ettenger
Harald Jüppner
Isidro B. Salusky
Publication date
01-11-2013
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 11/2013
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-013-2547-z

Other articles of this Issue 11/2013

Pediatric Nephrology 11/2013 Go to the issue

Erratum

Erratum to: Bilineal inheritance of PKD1 abnormalities mimicking autosomal recessive polycystic disease

Brief Report

Bilineal inheritance of PKD1 abnormalities mimicking autosomal recessive polycystic disease

Educational Review

Long-term outcomes of Shiga toxin hemolytic uremic syndrome

Brief Report

A novel hybrid CFHR1/CFH gene causes atypical hemolytic uremic syndrome

Original Article

Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome

Original Article

Acute kidney injury and its association with in-hospital mortality among children with acute infections